Gene Biotherapeutics (Gene Biotherapeutics) Predictability Rank

View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Predictability Rank?

Not Rated

Warren Buffett said many times that the companies he likes are:

1. Simple businesses that he understands
2. that have predictable and proven earnings and
3. with economic moat
4. those can be bought at a reasonable price.

It is hard to quantify "simple businesses that he (Buffett) understands", so we will focus on the other three characteristics instead. In GuruFocus Research: What worked in the market from 1998-2008? Part I: Introduction of Predictability Rank, we will show that the businesses that have predictable and proven earnings are usually also simple businesses that an average person could understand.

GuruFocus conducted a back test study of Warren Buffett's strategy of "buying good companies at fair prices" for the years from 1998-2008.

Gene Biotherapeutics Predictability Rank Calculation

In our database there are 2403 stocks that have been traded from Jan. 2, 1998 to Aug. 31, 2008. We have the complete 10-year financial data and trading prices of these companies for this period. We rank the predictability of these companies based on the consistency of their revenue per share and EBITDA (earning before interest, tax, depreciation and amortization) per share over the past ten fiscal years, and study the correlation between the stock performances and the predictability of the business.

Our study may be subject to these biases and assumptions:

Dividend yields are not counted for investment returns
Effects of price changes due to spin-offs may not be fully adjusted
Study is subjected to survivorship bias due to de-listing, bankruptcy, LBO, M&A, etc.

The correlation between business predictability and investment returns of a company is showed below.

Correlation Between Business Predictability and Investment Returns

	Predictables	Non-Predictable	All stocks
Total Number of stocks	570	1833	2403
Total Lost Money	61	830	891
Total Lost More Than 50%	18	412	430
Total Lost More Than 90%	4	86	90
Average Gain	260.6%	100.0%	138.1%
Median Gain	150.0%	13.0%	39.0%
Maximum Gain	2852.0%	11483.0%	11483.0%
Maximum Loss	-100.0%	-100.0%	-100.0%
Annualized Average Gain	12.7%	6.7%	8.4%
Annualized Median Gain	8.9%	1.1%	3.1%

For the 570 predictable companies, we have seen strong correlation between the predictability of businesses and the stock performances over the past 10 years, regardless of the valuation of business at 1998. Accordingly, we have ranked the business predictability from 5-star to 1-star, as shown in this table.

Predictability Rank	5-Star	4.5-Star	4-Star	3.5-Star	3-Star	2.5-Star	2-Star	1-Star (non-predictable)	Average among all
% Out of All 2403 Stocks	3.3%	2.9%	3.7%	3.3%	3.3%	3.7%	3.3%	76.3%	100%
% that are in Loss (10y)	3%	10%	8%	9%	11%	18%	16%	45%	37%
Average Gain (10y)	364.6%	330.9%	278.0%	235.1%	243.5%	227.8%	154.8%	100.0%	138.1%
Median Gain (10y)	238.5%	193.5%	171.0%	159.0%	132.5%	113.5%	87.0%	13.0%	39.0%
Maximum Gainer	2228.0%	2547.0%	2452.0%	2852.0%	2432.0%	1892.0%	1807.0%	11483.0%	11483.0%
Maximum Loser	-82.0%	-53.0%	-67.0%	-100.0%	-83.0%	-100.0%	-78.0%	-100.0%	-100.0%
Annualized Average Gain	15.4%	14.6%	13.2%	12.0%	12.2%	11.7%	9.1%	6.7%	8.4%
Annualized Median Gain	12.1%	10.6%	9.8%	9.3%	8.2%	7.3%	6.0%	1.1%	3.1%

For detailed information about each predictability rank, please go to GuruFocus Research: What worked in the market from 1998-2008? Part I: Introduction of Predictability Rank

Gene Biotherapeutics Predictability Rank Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's Predictability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Predictability Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121

Website

https://www.genebiotherapeutics.com

Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.

Executives

Andrew M Leitch	director	6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison	director	C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy	officer: Chief Financial Officer
Ronald I Simon	other: Former Director	485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten	director, officer: PRESIDENT and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines

From GuruFocus

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Gene Biotherapeutics Announces Sale Of Excellagen Technology Platform; Retains Commercialization Rights For Greater China And Russian Federation

By PRNewswire PRNewswire • 09-05-2018

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Baron Funds Comments on CarMax Inc.

By Holly LaFon • 02-06-2013